Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Improvement of diagnostic accuracy of Parkinson's disease on I-123-ioflupane single photon emission computed tomography (123I FP-CIT SPECT) using new Japanese normal database

Document Type : Original Article

Authors
Takao Kanzaki 1
Tetsuya Higuchi 2
Yasuyuki Takahashi 3
Takayuki Suto 1
Yoshito Tsushima 2
1 Department of Radiology, Gunma University Hospital, Gunma, Japan
2 Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Gunma, Japan
3 Department of Nuclear Medicine Technology, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan
10.22038/aojnmb.2019.43685.1290
Abstract
Objective(s): I-123-ioflupane single photon emission computed tomography (FP-CIT-SPECT) has been used to assess dopamine transporter (DAT) loss in Parkinson's disease. The specific binding ratio (SBR), a quantitative parameter of DAT density in the striatum, may be affected by differences in age, sex, and SPECT system. The purpose of this study was to evaluate the utility of FP-CIT-SPECT using the Japanese normal database (NDB) in the diagnosis of Parkinson's disease.
Methods: To standardize the quantitative outcome measures of DAT density obtained with different SPECT systems, striatal phantoms filled with striatal to background materials at ratios between 8:1 and 1:1 were measured using a gamma camera (ECAM) in our institute. Consecutive fifty patients (23 men and 27 women; age range, 40-86 years) with suspected PD undergoing FP-CIT SPECT brain imaging during the period from April to October 2016 were enrolled in this retrospective study. Their final diagnoses were PD in 28 patients and PD in 22 patients. SBRs of the patients were calculated using either new (Japanese database with different age and sex; NEWver) or old (non-Japanese database not specifying age and sex; OLDver) version software (AZE Virtual Place Hayabusa [DaTView], AZE, Ltd. Tokyo, Japan). The McNemar test was used to compare the diagnostic accuracy between old and new versions.
Results: Based on the phantom study, the calibrated SBR could be calculated by Y=1.25×Measured SBR+0.78. The sensitivities for OLDver and NEWver were 100% and 93%, respectively (p=0.5), and the specificities were 55% and 100% (p=0.002). The diagnostic accuracy of NEWver (96%) was better than that of OLDver (80%, p<0.001). 
Conclusion: FP-CIT-SPECT using the Japanese NDB improved the diagnostic accuracy of PD by improving specificity. 
Keywords
Japanese normal database
Parkinson's disease
DAT scan
Specific Binding Ratio
  1. Winogrodzka, A, Booij, J, & Wolters, E. C. (2005). Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson’s disease. Parkinsonism and Related Disorders, 11(8), 475–484.
  2. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I] beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001; 57: 2089–2094.
  3. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I] FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J Neural Transm 2001; 108: 1011–1019.
  4. R.B. Postuma, D. Berg, M. Stern, W. Poewe, C.W. Olanow, W. Oertel, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30 (12) (2015), pp. 1591–1601
  5. Benamer HTS, Patterson J, Grosset DG, Booij J, Bruin K De, Royen E Van, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2000; 15: 503–510.
  6. O’Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, et al. Is ioflupane123I injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 2014; 4: e005122.
  7. Brigo F, Matinella A, Erro R, Tinazzi M. [123I] FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: A meta-analysis. Eur J Neurol 2014; 21: 1369-1376.
  8. Varrone A, Dickson JC, Tossici-bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I] FP-CIT SPECT ( ENC-DAT ): age-related effects , gender differences and evaluation of different methods of analysis. 2013: 213-227.
  9. Tossici-Bolt L, Hoffmann SMA, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I] FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006; 33: 1491-1499.
  10. Matsuda H, Murata M, Mukai Y, Sako K, Ono H, Toyama H, et al. Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2018; 45: 1405-1416.
  11. Hudson HM, Larkin RS. Accelerated Image Reconstruction Using Ordered Subsets of Projection Data. IEEE Trans Med Imaging 1994; 13: 601-609.
  12. Tossici-Bolt L, Dickson JC, Sera T, Nijs R De, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging 2011; 38: 1529-1540.
  13. Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [ 123 I ] FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys 2017; 4(1): 8.
  14. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al: Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases：A 3-year European multicenter study with repeat (123I) FP-CIT SPECT. Mov Disord 2009: 24: 500-508.
  15. Asahi T, Kashiwazaki D, Yoneyama T, Noguchi K, Kuroda S. Importance of 123I-ioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson’s Disease. Neurologia Medico-Chirurgica 2016: 56(3), 125-131.
  16. Murakami H, Kimura A, Yasumoto T, Miki A, Yamamoto K, Ito N, et al. Usefulness Differs Between the Visual Assessment and Specific Binding Ratio of 123I-Ioflupane SPECT in Assessing Clinical Symptoms of Drug-Naïve Parkinson’s Disease Patients. Front Aging Neurosci 2018; 10: 1-8.
  17. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis. Park Relat Disord. 2012; 18: 494-500.
  18. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Giuda D Di, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis. Clin Auton Res 2012; 22: 43-55.
  19. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583-588.
  20. Takahashi M, Ikemura M, Oka T, Uchihara T, Wakabayashi K, Kakita A, et al. Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J Neurol Neurosurg Psychiatry 2015; 86: 939-944.
  21. Bosman T, Laere K Van, Santens P. Anatomically standardised99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging 2003; 30: 16-24.
  22. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson’s disease with and without dementia, and Alzheimer’s disease. Clin Neurol Neurosurg 2005; 107: 396-403.
  23. Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, et al. Heterogeneous factors in dementia with Parkinson’s disease: IMP-SPECT study. Park Relat Disord 2007; 13: 174-181.
  24. Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson’s disease. Hum Brain Mapp 2012; 33: 727-739.
  25. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 2002; 52(7): 759-63.
  26. Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999; 64(4): 803-12.

Asia Oceania Journal of Nuclear Medicine and Biology
Volume 8, Issue 2
July 2020
Pages 95-101